Dr. Martens maintains guidance as US market grows

Dr. Martens has said its full year guidance remains unchanged in a statement ahead of its annual general meeting today.

The footwear brand said trading since the start of its current financial year has been in line with expectations as it remains on track to deliver on its strategic objectives for the year.

These include driving full price revenue mix in UK and DACH, introducing an innovative new sandals range, launching new retail concepts in key cities around the world, and unlocking operating model and technology benefits.

It added: “Our largest market, the USA, continues to grow, with wholesale particularly encouraging. Our largest Asian markets, Japan and South Korea, are both performing well. Our European markets are performing as expected, against a challenging consumer backdrop.”

In May, Dr. Martens reported that it had returned to profit growth in the year to 29 March as it continued to move from a channel led to a “consumer-first” operating model. Adjusted pre-tax profit increased by 61.3% to £55 million in the period, which was in line with expectations.